PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMeprobamate
Meprobamate
Amosene, Bamate, Equagesic, Equanil, Mepriam, Meprospan, Micrainin, Milprem, Miltown, Neuramate, Pmb, Q-gesic, Tranmep (meprobamate) is a small molecule pharmaceutical. Meprobamate was first approved as Micrainin on 1982-01-01. It is used to treat anxiety disorders, headache, muscle rigidity, muscle spasticity, and spasm in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aspirin
+
Meprobamate
Tradename
Company
Number
Date
Products
EQUAGESICSun Pharmaceutical IndustriesN-011702 DISCN1983-12-29
1 products
Hide discontinued
Estrogens
+
conjugated
+
Meprobamate
Tradename
Company
Number
Date
Products
MILPREM-400Medpointe Pharm HlcN-011045 DISCN1982-01-01
1 products
MILPREM-200Medpointe Pharm HlcN-011045 DISCN1982-01-01
1 products
PMB 400WyethN-010971 DISCN1982-01-01
1 products
PMB 200WyethN-010971 DISCN1982-01-01
1 products
Hide discontinued
Meprobamate
Tradename
Company
Number
Date
Products
MEPROBAMATEChartwell PharmaceuticalsN-014882 DISCN1982-01-01
2 products
MEPROBAMATEA.H. Robins CompanyN-015426 DISCN1982-01-01
2 products
NEURAMATEHalsey DrugN-014359 DISCN1982-01-01
2 products
MEPROBAMATEHeather DrugN-016928 DISCN1982-01-01
1 products
MEPROBAMATEImpax LaboratoriesN-014322 DISCN1982-01-01
2 products
MEPROBAMATETevaN-015438 DISCN1982-01-01
2 products
MEPROBAMATEMallard PharmaceuticalsN-015072 DISCN1982-01-01
1 products
MILTOWNMedpointe Pharm HlcN-009698 DISCN1982-01-01
2 products, RLD
MEPROSPANMedpointe Pharm HlcN-011284 DISCN1982-01-01
2 products
MEPROBAMATEMK LaboratoriesN-014368 DISCN1982-01-01
2 products
MEPROBAMATEPrivate FormulationsN-014601 DISCN1982-01-01
1 products
MEPROBAMATESandozN-014547 DISCN1982-01-01
2 products
TRANMEPSolvay PharmaceuticalsN-016249 DISCN1982-01-01
1 products
MEPROBAMATEStanlabs PharmaceuticalN-014474 DISCN1982-01-01
2 products
MEPRIAMTevaN-016069 DISCN1982-01-01
1 products
MEPROBAMATEBausch Health CompaniesN-015139 DISCN1982-01-01
2 products
MEPROBAMATEWest-Ward PharmaceuticalN-015417 DISCN1982-01-01
2 products
EQUANILWyethN-010028 DISCN1982-01-01
2 products
EQUANILWyethN-012455 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
equagesic2008-01-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anxiety disordersEFO_0006788D001008F41.1
headacheHP_0002315D006261R51
muscle rigidityHP_0002063D009127—
muscle spasticityHP_0001257D009128—
spasm—D013035M62.83
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05B: Anxiolytics
— N05BC: Carbamate anxiolytics
— N05BC01: Meprobamate
— N05BC51: Meprobamate, combinations
— N05C: Hypnotics and sedatives
— N05CX: Hypnotics and sedatives in combination, excl. barbiturates
— N05CX01: Meprobamate, combinations
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9—11——1
Transient ischemic attackD002546EFO_0003764G45.9—11——1
Patent foramen ovaleD054092HP_0001655Q21.12—11——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40————11
BradycardiaD001919HP_0001662R00.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMeprobamate
INNmeprobamate
Description
Meprobamate is an organic molecular entity.
Classification
Small molecule
Drug classtranquilizers/antiepileptics (propanediol and pentanediol groups)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCC(C)(COC(N)=O)COC(N)=O
Identifiers
PDB—
CAS-ID57-53-4
RxCUI—
ChEMBL IDCHEMBL979
ChEBI ID—
PubChem CID4064
DrugBankDB00371
UNII ID9I7LNY769Q (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Meprobamate
+
Aspirin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Meprobamate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,564 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,338 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use